Evidence map›Paper›PMID 34201646›Full record

ReviewInternational journal of molecular sciences2021

Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.

Céline Delaitre, Michel Boisbrun, Sandra Lecat, François Dupuis

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. The ATMolecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Céline DelaitreCITHEFOR, Université de Lorraine, F-54000 Nancy, France.
Michel BoisbrunCNRS, L2CM, Université de Lorraine, F-54000 Nancy, France.ORCID 0000-0001-6588-0027
Sandra LecatBiotechnologie et Signalisation Cellulaire, UMR7242 CNRS/Université de Strasbourg, 300 Boulevard Sébastien Brant, CS 10413, CEDEX, 67412 Illkirch-Graffenstaden, France.
François DupuisCITHEFOR, Université de Lorraine, F-54000 Nancy, France.ORCID 0000-0003-1947-3839
Centre National de la Recherche Scientifique · FRCibles thérapeutiques, formulation et expertise préclinique du médicament

Funding

Agence Nationale de la Recherche ANR-10-IDEX-0002Agence Nationale de la Recherche ANR-20-SFRI-0012
6 · The paper itself

Abstract

The physiological and pathophysiological relevance of the angiotensin II type 1 (AT

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsbeta-ArrestinsBrain Injuries, TraumaticCardiovascular DiseasesHumansIntracranial AneurysmMolecular Targeted TherapyReceptor, Angiotensin, Type 1Signal TransductionStrokeAngiotensin II Type 1 Receptor Blockersbeta-ArrestinsReceptor, Angiotensin, Type 1Ang-(1–7)Angiotensin IIAT1 receptorbeta-arrestinbiased agonismcerebrovascular diseaseRASTRV023TRV027

Identifiers

PMID34201646
PMCPMC8269339
OpenAlexW3173822292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.